Related Experiment Video
Updated: Jun 26, 2026
Isolation and Immortalization of Patient-derived Cell Lines from Muscle Biopsy for Disease Modeling
Published on: January 18, 2015
Multiplicity of experimental approaches to therapy for genetic muscle diseases and necessity for population screening
1Centre for Medical Research, Western Australian Institute for Medical Research, QEII Medical Centre, University of Western Australia, B Block, Hovea Lane, Nedlands, Western Australia, 6009, Australia. nlaing@cyllene.uwa.edu.au
Abstract:
Currently a multiplicity of experimental approaches to therapy for genetic muscle diseases is being investigated. These include replacement of the missing gene, manipulation of the gene message, repair of the mutation, upregulation of an alternative gene and pharmacological interventions targeting a number of systems. A number of these approaches are in current clinical trials. There is considerable anticipation that perhaps more than one of the approaches will finally prove of clinical benefit, but there are many voices of caution. No matter which approaches might ultimately prove effective, there is a consensus that for most benefit to the patients it will be necessary to start treatment as early as possible. A consensus is also developing that the only way to do this is to implement population-based newborn screening to identify affected children shortly after birth. Population-based newborn screening is currently practised in very few places in the world and it brings with it implications for prevention rather than cure of genetic muscle diseases.
Insights
Investigational therapies for genetic muscle diseases are progressing, with early intervention being key. Population-based newborn screening is crucial for timely diagnosis and effective management of these conditions.
Area of Science:
- Genetics
- Neurology
- Pharmacology
Background:
- Multiple experimental therapeutic strategies for genetic muscle diseases are under investigation.
- Approaches include gene replacement, gene editing, and pharmacological interventions, with some already in clinical trials.
Purpose of the Study:
- To review current therapeutic approaches for genetic muscle diseases.
- To highlight the importance of early diagnosis and intervention.
Main Methods:
- Review of current experimental therapeutic approaches.
- Discussion of clinical trial progress.
- Analysis of the role of newborn screening.
Main Results:
- Various gene- and cell-based therapies are in development and clinical trials.
- Early treatment initiation is critical for maximizing patient benefit.
- Population-based newborn screening is emerging as a key strategy for early identification.
Conclusions:
- While promising, therapeutic advancements require cautious optimism.
- Early detection through newborn screening is essential for effective prevention and management of genetic muscle diseases.
- Newborn screening shifts the paradigm towards prevention over cure.
